Prostate cancer treatment could cure 3,000 men a year
A BREAKTHROUGH in treatment for prostate cancer could cure thousands of men whose disease was thought to be incurable, research suggests.
The Institute of Cancer Research said the findings were a “great leap forward” that could help around 3,000 men a year for whom there would otherwise be little hope.
The pioneering study, with The Royal Marsden, found that the highly targeted form of radiotherapy, which shapes radiation beams to tumours, could stop the disease in its tracks. Prostate cancer is the most common form of cancer in men, with 47,000 diagnoses a year. Depending how far disease has spread, and how aggressive it is, men are offered hormonal treatment, surgery, radiotherapy or a combination of treatments.
But when cancer has spread to the pelvis, conventional treatment becomes too risky, as it can damage the bowel.
The study found that intensity modulated radiotherapy (IMRT) was able to give a high dose of radiation directly to cancer cells while protecting surrounding healthy tissue, thereby cutting the risk of side effects. In the study on 447 men, 71 per cent of patients with
prostate cancer were alive and completely free from disease five years after treatment with IMRT.
When the trial began, many of the patients were considered incurable, researchers said. And just eight to 16 per cent of those in the trial suffered issues with their bladder or bowel.
The trial found that IMRT could safely be given to the pelvis – a common site for prostate cancer cells to spread – to help stop the disease going further.
After an average of 8.5 years of follow-up, 87 per cent of men were alive, according to the study, published in the International Journal of Radiation Oncology, Biology, Physics.
Since the trial began in 2000, the treatment is increasingly offered to some patients by major cancer centres, but until now the benefits for those thought incurable has not been known.
David Dearnaley, study leader, professor of uro-oncology at the ICR and consultant clinical oncologist at The Royal Marsden, said: “Our trial was one of the first of this revolutionary radiotherapy technique, which was pioneered by colleagues here at the ICR and The Royal Marsden.
“This technique has already proven to be a game-changer for men with prostate cancer and the work done here has already been carried forward into later-stage phase II and phase III trials. I’m excited to see this treatment become available to every man with prostate cancer who could benefit from it.”
Changes in use of the treatment had meant a “complete revolution” in the way it was delivered, with doses now delivered in just two minutes, he said.
Prof Paul Workman, of the ICR, said: “Radiotherapy is often seen as perhaps old-fashioned and crude compared with other cancer treatments – but nothing could be further from the truth.”
Dr Matthew Hobbs, deputy director of research at Prostate Cancer UK, called for larger trials to produce definitive answers about the benefits of the treatment and its suitability for different cases.